You are here
ARGINOX PHARMACEUTICALS, INC.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Therapy for Improving Vascular Function in Diabetes
Amount: $128,203.00DESCRIPTION (provided by applicant): ArgiNOx is a recently-formed Wisconsin-based biotech startup that seeks to develop novel therapies for cardiovascular and inflammatory conditions resulting from in ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Use of NOS inhibitor to expand hematopoietic stem cells
Amount: $192,938.00DESCRIPTION (provided by applicant): Hematopoietic cell-supported therapy is employed for a broad spectrum of malignancies and hematological disease. However, the approach is limited by the availabili ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
NOS Inhibitor Therapy for Cardiogenic Shock
Amount: $271,044.00DESCRIPTION (provided by applicant): This is a Fast-track Phase I application from ArgiNOx Inc. to develop a novel pharmacotherapy that may save lives of tens of thousands of patients that develop car ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health